Newborn and Infant Nursing Reviews
Volume 6, Issue 3 , Pages 158-162 , September 2006

To Go Against Nature: Manipulating the Neonatal Ductus Arteriosus with Prostaglandin

References 

  1. Hammerman C. Patent ductus arteriosus: clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol. 1995;22:457–477
  2. Roehl SL, Townsend RJ. Alprostadil (Prostin VR pediatric sterile solution, the Upjohn Company). Drug Intell Clin Pharm. 1982;16:823–832
  3. Clyman RI. Ductus arteriosus: current theories of prenatal and postnatal regulation. Semin Perinatol. 1987;11:64–71
  4. Reller MD, Rice MJ, McDonald RW. Review of studies evaluating ductal patency in the premature infant. J Pediatr. 1993;122:s59–s62
  5. Gentile R, Stevenson G, Dooley T, et al. Pulsed Doppler echocardiographic determination of the time of ductal closure in normal newborn infants. J Pediatr. 1981;98:443–448
  6. Lim MK, Hanretty K, Houston AB, et al. Intermittent ductal patency in healthy newborn infants: demonstration by colour Doppler flow mapping. Arch Dis Child. 1992;67(10 Spec No):1217–1218
  7. Leonhardt A, Glaser A, Wegmann M, et al. Expression of prostanoid receptors in human ductus arteriosus. Br J Pharmacol. 2003;138:655–659
  8. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev. 1998;50:35–58
  9. Van Overmeire B, Chemtob S. The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med. 2005;10:177–184
  10. Elliott RB, Starling MB, Neutze JM. Medical manipulation of the ductus arteriosus. Lancet. 1975;1:140–142
  11. Heymann MA, Berman W, Rudolph AM, Whiman V. Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities. Circulation. 1979;59:169–173
  12. Hallidie-Smith KA. Prostaglandin E1 in suspected ductus dependent cardiac malformation. Arch Dis Child. 1984;59:1020–1026
  13. Penny DJ, Shekerdemian LS. Management of the neonate with symptomatic congenital heart disease. Arch Dis Child Fetal Neonatal Ed. 2001;84:F141–F145[Retrieved February, 2006 from www.archdischild.com]
  14. Taketomo CK, Hoding JH, Kraus DM. Pediatric dosage handbook: including neonatal dosing, drug administration & extemporaneous preparations. 10th ed.. Hudson (Ohio): Lexi-Comp; 2003;
  15. Zenk KE, Sills JG, Koeppel RM. Neonatal medications and nutrition. 3rd ed.. Santa Rosa (Calif): NICU Ink; 2003;
  16. Golub M, Zia P, Matsuno M, Horton R. Metabolism of prostaglandins A1 and E1 in man. J Clin Invest. 1975;56:1404–1410
  17. Kramer HH, Sommer M, Rammos S, et al. Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease. Eur J Pediatr. 1995;154:700–707
  18. Cawello W, Schweer H, Muller R, et al. Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects. Eur J Clin Pharmacol. 1994;46:275–277
  19. Barst RJ, Gersony WM. The pharmacologic treatment of patent ductus arteriosus: a review of the evidence. Drugs. 1989;38:249–266
  20. Saji T, Matsuura H, Hoshino K, Yamamoto S, Ishikita T, Matsuo N. Oral prostaglandin E1 derivative (OP-1206) in an infant with double outlet right ventricle and pulmonary stenosis. Effect on ductus-dependent pulmonary circulation. Jpn Heart J. 1991;32:735–740
  21. Chino Y, Minagawa T, Kohno Y, et al. Vasodilating effect and tissue accumulation of prostaglandin E1 incorporated in lipid microspheres on the rat ductus arteriosus. Jpn J Pharmacol. 1999;81:107–114
  22. Tohyama M, Baba A, Tsuno T, et al. Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia. Eur J Pediatr. 1993;152:877–879
  23. Mandai H, Kinouchi K, Kawaraguchi Y, et al. An extremely low birth weight infant with pulmonary atresia complicated with necrotizing enterocolitis. Masui. 2001;50:1133–1135
  24. Lim DS, Kulik TJ, Kim DW, et al. Aminophylline for the prevention of apnea during prostaglandin E1 infusion. Pediatrics. 2003;112(1 Pt 1):e27–e29
  25. Product information . Prostin VR pediatric. Kalamazoo (Mich): The UpJohn Company; 1995;
  26. Lewis AB, Freed MD, Heymann RA, Roehl SL, Kensey RC. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease. Circulation. 1981;64:893–898
  27. Miller SF. Resolution of calcific brown fat necrosis associated with prostaglandin therapy for cyanotic congenital heart disease in neonates: report of two cases. Pediatr Radiol. 2004;34(11):919–923
  28. Arav-Boger R, Baggett HC, Spevak PJ, Willoughby RE. Leukocytosis caused by prostaglandin E1 in neonates. J Pediatr. 2001;138:263–265
  29. Carter EL, Garzon MC. Neonatal urticaria due to prostaglandin E1. Pediatr Dermatol. 2000;17:58–61
  30. Kaufman MB, El-Chaar GM. Bone and tissue changes following prostaglandin therapy in neonates. Ann Pharmacother 1996;30:269–74,277.
  31. Peled N, Dagan O, Babyn P, et al. Gastric-outlet obstruction induced by prostaglandin therapy in neonates. N Engl J Med. 1992;327:505–510
  32. Joshi A, Berdon WE, Brudnicki A, et al. Gastric thumbprinting: diffuse gastric wall mucosal and submucosal thickening in infants with ductal-dependent cyanotic congenital heart disease maintained on long-term prostaglandin therapy. Pediatr Radiol. 2002;32:405–408
  33. Heffelfinger S, Hawkins EP, Nihill M, Langston C. Pulmonary vascular changes associated with prolonged prostaglandin E1 treatment. Pediatr Pathol. 1987;7:165–173
  34. Tappero EP, Honeyfield ME. Physical assessment of the newborn: a comprehensive approach to the art of physical examination. 3rd ed.. Santa Rosa (Calif): NICU Ink; 2003;
  35. Rikard DH. Nursing care of the neonate receiving prostaglandin E1 therapy. Neonatal Netw. 1993;12:17–22

PII: S1527-3369(06)00061-4

doi: 10.1053/j.nainr.2006.05.001

Newborn and Infant Nursing Reviews
Volume 6, Issue 3 , Pages 158-162 , September 2006

Article Tools

* Image Usage & Resolution